Pharmacy Times November 24, 2021
Ferkhanda Najib, PharmD

Reports of depression, anxiety and stress have surged since the beginning of the COVID-19 pandemic in 2020.

Reports of depression, anxiety and stress have surged since the beginning of the COVID-19 pandemic in 2020. In a Kaiser Family Foundation (KFF) poll in February 2021, 4 out of 10 Americans reported that they were experiencing symptoms of anxiety disorder or depressive order, compared with 1 out of 10 in January 2019.1

The spike in adverse mental health symptoms has led to increased use of behavioral health medications. This, in turn, has resulted in more patient questions and concerns and an expanded need for monitoring to ensure that these medications do not interact poorly with other medications.

Population Impact Varies

Over the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Mental Health, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Involuntary Medical Hold: The Next Step in Mental Health Parity?
BHB VALUE: Our Journey to Value: Insights from 100 Industry Leaders
Addressing Pregnancy And Parenting In Mental Health Care: Perspectives Of Women With Serious Mental Illness
Is precision psychiatry possible?
BHB VALUE: Breaking Barriers: Bridging Gaps in Behavioral Health Equity for Maternal Health

Share This Article